Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: Toxicity and MR imaging findings

S. M. Roman-Goldstein, P. A. Barnett, C. I. McCormick, M. J. Ball, F. Ramsey, Edward Neuwelt

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Osmotic blood-brain barrier disruption with intraarterial chemotherapy has been shown to be beneficial in the treatment of malignant brain tumors. Imaging blood-brain barrier disruption is necessary to document the extent and degree of disruption and to correlate disruption with drug delivery. The present study evaluated blood-brain barrier disruption with gadopentetate dimeglumine-enhanced MR imaging and the associated toxicity of gadopentetate dimeglumine administration. Blood-brain barrier disruption was performed in seven dogs for imaging analysis and 17 dogs for toxicity evaluation. In the absence of gadopentetate dimeglumine administration, blood-brain barrier disruption could not be imaged. Enhanced MR imaging with a gadopentetate dimeglumine dose of 0.1 mmol/kg provided good images of disruption at an imaging time of 3 hr after disruption. However, when gadopentetate dimeglumine was given intravenously in conjunction with osmotic blood-brain barrier disruption, there was a statistically significant (p = .02) dose-dependent increase in the frequency of seizures, with 50% of the animals who received 0.1 mmol/kg and 75% who received 0.2 mmol/kg developing delayed seizures. Our findings show that, as with ionized iodinated CT contrast agents, gadopentetate dimeglumine is associated with toxicity when used in conjunction with osmotic blood-brain barrier disruption in dogs. Such toxicity may be a contraindication to the use of gadopentetate dimeglumine for monitoring patients with osmotically induced disruption of the blood-brain barrier.

Original languageEnglish (US)
Pages (from-to)885-890
Number of pages6
JournalAmerican Journal of Neuroradiology
Volume12
Issue number5
StatePublished - 1991

Fingerprint

Gadolinium DTPA
Blood-Brain Barrier
Dogs
Seizures
Physiologic Monitoring
Brain Neoplasms
Contrast Media
Drug Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption : Toxicity and MR imaging findings. / Roman-Goldstein, S. M.; Barnett, P. A.; McCormick, C. I.; Ball, M. J.; Ramsey, F.; Neuwelt, Edward.

In: American Journal of Neuroradiology, Vol. 12, No. 5, 1991, p. 885-890.

Research output: Contribution to journalArticle

Roman-Goldstein, S. M. ; Barnett, P. A. ; McCormick, C. I. ; Ball, M. J. ; Ramsey, F. ; Neuwelt, Edward. / Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption : Toxicity and MR imaging findings. In: American Journal of Neuroradiology. 1991 ; Vol. 12, No. 5. pp. 885-890.
@article{4ef946dbbc5c41ea84c3573a9253d310,
title = "Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: Toxicity and MR imaging findings",
abstract = "Osmotic blood-brain barrier disruption with intraarterial chemotherapy has been shown to be beneficial in the treatment of malignant brain tumors. Imaging blood-brain barrier disruption is necessary to document the extent and degree of disruption and to correlate disruption with drug delivery. The present study evaluated blood-brain barrier disruption with gadopentetate dimeglumine-enhanced MR imaging and the associated toxicity of gadopentetate dimeglumine administration. Blood-brain barrier disruption was performed in seven dogs for imaging analysis and 17 dogs for toxicity evaluation. In the absence of gadopentetate dimeglumine administration, blood-brain barrier disruption could not be imaged. Enhanced MR imaging with a gadopentetate dimeglumine dose of 0.1 mmol/kg provided good images of disruption at an imaging time of 3 hr after disruption. However, when gadopentetate dimeglumine was given intravenously in conjunction with osmotic blood-brain barrier disruption, there was a statistically significant (p = .02) dose-dependent increase in the frequency of seizures, with 50{\%} of the animals who received 0.1 mmol/kg and 75{\%} who received 0.2 mmol/kg developing delayed seizures. Our findings show that, as with ionized iodinated CT contrast agents, gadopentetate dimeglumine is associated with toxicity when used in conjunction with osmotic blood-brain barrier disruption in dogs. Such toxicity may be a contraindication to the use of gadopentetate dimeglumine for monitoring patients with osmotically induced disruption of the blood-brain barrier.",
author = "Roman-Goldstein, {S. M.} and Barnett, {P. A.} and McCormick, {C. I.} and Ball, {M. J.} and F. Ramsey and Edward Neuwelt",
year = "1991",
language = "English (US)",
volume = "12",
pages = "885--890",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "5",

}

TY - JOUR

T1 - Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption

T2 - Toxicity and MR imaging findings

AU - Roman-Goldstein, S. M.

AU - Barnett, P. A.

AU - McCormick, C. I.

AU - Ball, M. J.

AU - Ramsey, F.

AU - Neuwelt, Edward

PY - 1991

Y1 - 1991

N2 - Osmotic blood-brain barrier disruption with intraarterial chemotherapy has been shown to be beneficial in the treatment of malignant brain tumors. Imaging blood-brain barrier disruption is necessary to document the extent and degree of disruption and to correlate disruption with drug delivery. The present study evaluated blood-brain barrier disruption with gadopentetate dimeglumine-enhanced MR imaging and the associated toxicity of gadopentetate dimeglumine administration. Blood-brain barrier disruption was performed in seven dogs for imaging analysis and 17 dogs for toxicity evaluation. In the absence of gadopentetate dimeglumine administration, blood-brain barrier disruption could not be imaged. Enhanced MR imaging with a gadopentetate dimeglumine dose of 0.1 mmol/kg provided good images of disruption at an imaging time of 3 hr after disruption. However, when gadopentetate dimeglumine was given intravenously in conjunction with osmotic blood-brain barrier disruption, there was a statistically significant (p = .02) dose-dependent increase in the frequency of seizures, with 50% of the animals who received 0.1 mmol/kg and 75% who received 0.2 mmol/kg developing delayed seizures. Our findings show that, as with ionized iodinated CT contrast agents, gadopentetate dimeglumine is associated with toxicity when used in conjunction with osmotic blood-brain barrier disruption in dogs. Such toxicity may be a contraindication to the use of gadopentetate dimeglumine for monitoring patients with osmotically induced disruption of the blood-brain barrier.

AB - Osmotic blood-brain barrier disruption with intraarterial chemotherapy has been shown to be beneficial in the treatment of malignant brain tumors. Imaging blood-brain barrier disruption is necessary to document the extent and degree of disruption and to correlate disruption with drug delivery. The present study evaluated blood-brain barrier disruption with gadopentetate dimeglumine-enhanced MR imaging and the associated toxicity of gadopentetate dimeglumine administration. Blood-brain barrier disruption was performed in seven dogs for imaging analysis and 17 dogs for toxicity evaluation. In the absence of gadopentetate dimeglumine administration, blood-brain barrier disruption could not be imaged. Enhanced MR imaging with a gadopentetate dimeglumine dose of 0.1 mmol/kg provided good images of disruption at an imaging time of 3 hr after disruption. However, when gadopentetate dimeglumine was given intravenously in conjunction with osmotic blood-brain barrier disruption, there was a statistically significant (p = .02) dose-dependent increase in the frequency of seizures, with 50% of the animals who received 0.1 mmol/kg and 75% who received 0.2 mmol/kg developing delayed seizures. Our findings show that, as with ionized iodinated CT contrast agents, gadopentetate dimeglumine is associated with toxicity when used in conjunction with osmotic blood-brain barrier disruption in dogs. Such toxicity may be a contraindication to the use of gadopentetate dimeglumine for monitoring patients with osmotically induced disruption of the blood-brain barrier.

UR - http://www.scopus.com/inward/record.url?scp=0026043660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026043660&partnerID=8YFLogxK

M3 - Article

C2 - 1950917

AN - SCOPUS:0026043660

VL - 12

SP - 885

EP - 890

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 5

ER -